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Before the era of rituximab, high-dose chemotherapy
with autologous stem cell transplantation (ASCT) served as
the standard of care for relapsed, aggressive diffuse large
B cell lymphoma (DLBCL) that was chemosensitive to salvage
chemotherapy. Dramatic improvement has been observed
with the addition of rituximab to chemotherapy. Neverthe-
less, depending on clinical and biological prognostic factors,
some patients will not be cured because they are refractory
to ﬁrst-line treatment or because they have relapsed. Could a
different behavior be expected in relapsed disease because of
the introduction of rituximab, thus questioning the place of
auto-transplantation? The COllaborative trial in Relapsed
Aggressive Lymphoma (CORAL) study was designed as an
international effort to determine which salvage regimens
should be proposed to patients with relapsed DLBCL and to
evaluate the place of rituximab for maintenance after ASCT,
but some of the conclusions were disappointing. The sec-
ondary international prognostic index (sIPI), a relapse/re-
fractory episode <12 months from diagnosis, and prior
rituximab exposure were signiﬁcantly associated with poor
response to salvage and survival in multivariate analyses.
Data from the diagnosis of relapse or failure, including all
patients who underwent or did not undergo transplantation,
have been reported [1]. An especially poor outcome was
observed for patients with prior exposure to rituximab as a
ﬁrst-line treatment and who relapsed or were refractory
<12 months from diagnosis, with 5-year progression-freeDOI of original article: http://dx.doi.org/10.1016/j.bbmt.2014.06.036.
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Does this result mean that consolidation with stem
transplantation after salvage is of limited value for this group
of patients? Hamadani et al. [2] reported the analysis of the
Center for International Blood and Marrow Transplant
Research registry data from 2 cohorts of patients who
underwent transplantation with DLBCL and who were pre-
viously exposed to rituximab, including 300 patients with
early relapses <12 months (EFR) and 216 patients with late
relapses (LRF). All of these patients had been either partial
responders (n ¼ 267) or complete responders (CR) (n ¼ 249)
to salvage chemotherapy before transplantation. The 3-year
PFS for the EFR group was 44%, compared with 52% for the
LRF group (P¼ .08). If the PFS for the EFR cohortwas inferior, it
was only apparent during the initial part of the curve, after
ASCT (<9 months, P < .001); later, the outcome was similar
for the 2 groups. The same observationwas described for the
50% 3-year OS of the EFR group versus the 67% for the LRF
group (P < .001). The authors concluded that ASCT provides
durable disease control, regardless of the timing of relapse in
DLBCL patients treatedwithﬁrst-line immunochemotherapy.
However, the authors noted that patients in the EFR group
had a higher rate of relapse than the LRF group in the early
period (6 to 9months) after transplantation. These results are
still in agreement with those of the CORAL study; the 3-year
PFS for 242 patients submitted to “per protocol” trans-
plantation was 52% [3]. The event-free survival, PFS, and OS
were affected to a lesser extent by the previously described
factors: prior rituximab exposure and sIPI. The 3-year OS was
76% and 51% for sIPI 0-1 and 2-3 factors, respectively
(P¼ .0003). The difference between early and late relapsewas
less pronounced (P ¼ .50; hazard ratio, 1.59), but a higher
relapse rate within 12 months after transplantation was
observed for the early relapse group. At 5 years, at the end of
the curves, a similar “plateau” was observed. However, the
Cox model revealed that only sIPI 2 and 3 remained signiﬁ-
cant (P ¼ .0004; hazard ratio, 2.252). The main limitation of
these transplantation strategies is the need of a signiﬁcant
level of response to the salvage regimen to reach complete
remission or a good partial response before ASCT.
Obviously, we are at the end of the efﬁcacy of salvage
regimens with the current chemotherapy, and no 1 regimen
Logrank P = .0003
Figure 1. Overall survival (OS) in months according to the transplantation status of DLBCL patients after administration of a third-line regimen in the CORAL study. No
indicates no transplantation performed; yes, transplantation performed [4].
C. Gisselbrecht / Biol Blood Marrow Transplant 20 (2014) 1667e16701668is superior to the other. Notably, more than 45% of patients
must receive more than 2 lines of therapy to reach a che-
mosensitive status. Apparently, the number of lines was not
an adverse prognostic factor if ASCT was performed. The
CORAL protocol was designed with no more than 2 lines
before transplantation, which may have been a limitation.
Recently, we looked at the outcome of 145 patients who
failed rituximab, ifosfamide, carboplatin, etoposide (RICE) or
rituximab, dexamethasone, cytarabine, cisplatin (RDHAP),
and surprisingly, a variety of third-line regimens produced a
43% response rate with 29% CR [4]. In 64 recorded patients, a
consolidation with transplantation was performed “off pro-
tocol,” producing a median OS of 11.18 months and a 1-year
OS of 41.6%. For the patients who were CRs, the median OS
was not reached. The difference was highly signiﬁcant for
patients who had not undergone transplantation, with a
median OS of 5 months (P ¼ .003) (Figure 1).
Long-term disease control can be observed, especially in
patients achieving CR after third-line treatment. This
approach, ie, salvage chemotherapy aimed at achieving a
response followed by transplantation, should be encouraged
in these patients, even in the rituximab era. However, there is
an urgent need for new drugs that improve salvage efﬁcacy.
On the other hand, these ﬁndings argue for the development
of novel consolidation and/or maintenance strategies toprevent relapses after transplantation. Unfortunately, 2 cur-
rent, randomized studies using rituximab for maintenance
after transplantation failed to demonstrate a signiﬁcant
beneﬁt in survival [3,5]. Targeted drugs are being developed,
and most of them have limited efﬁcacy in DLBCL or are
restricted to subtypes. Allogeneic transplantation may be
another method for reducing post-transplantation relapse; it
has had some encouraging results and resulted in disease
control at 3 years of 35% in people who had poor prognosis
relapses [6]. Although this method does solve the issue of
efﬁcacy of salvage before transplantation, is restricted to pa-
tients younger than those in this report, in which more than
50% of the patients were>60 years old. This very large series
clariﬁes some of the main issues concerning the efﬁcacy of
transplantation in the rituximab era. Even for poor prognosis
relapses, if patients can achieve CR or partial response before
transplantation, long-termsurvival canbe expected for 50%of
the patients, with a 3-year PFS of 44% for the EFR group. Even
though progress still must be made, ASCT remains the stan-
dard of care for patients with relapsed DLBCL.
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is a potentially curative therapy for patients with a variety of
malignant and nonmalignant hematological disorders. Over
the last decades, substantial improvement has been achieved
in SCT outcomes [1]. A larger proportion of SCT recipients are
now long-term survivors and more attention is given to is-
sues of quality of life and late complications. Second malig-
nancies are a rare but well-deﬁned late complication after
allogeneic SCT with myeloablative conditioning (MAC), ac-
counting for 5% to 10% of late deaths [2-6]. The incidence is
gradually increasing after SCT, with no apparent plateau. The
Center for International Blood and Marrow Transplant
Research and the Fred Hutchinson Cancer Research Center
conducted the largest analysis to date of second malig-
nancies among 28,874 SCT recipients [2]. Second malig-
nancies were observed in 189 patients, with a cumulative
incidence of 1.0% at 10 years, 2.2% at 15 years, and 3.3% at 20
years. This rate was 2.1 higher than expected in a matched
general population. The majority of patients in this analysis
were given total body irradiation (TBI) during conditioning.
Signiﬁcantly elevated risks were observed for tumors of the
oral cavity, liver, central nervous system, thyroid, bone, soft
tissues, and melanoma of the skin. In a follow-up report,
Majhail et al. studied 4318 patients with acute myelogenous
leukemia (AML) and chronic myelogenous leukemia who
were given allogeneic SCT with chemotherapy-based MAC
consisting of busulfan and cyclophosphamide [3]. Sixty-six
patients had a second malignancy, with a 10-yearcumulative incidence of 1.2% in AML and 2.4% in chronic
myelogenous leukemia,1.4 times higher than expected in the
general population. Signiﬁcantly elevated risks were
observed for tumors of the oral cavity, esophagus, lung, soft
tissue, and brain. More recently, Atsuta et al. reported on 269
second malignancies among 17,545 Japanese SCT recipients,
with a cumulative incidence 1.7% at 10 years, which was 1.8
more than a matched general population [6]. Risks were
higher for oral cavity, esophageal, colon, skin, and brain
cancers. Thus, despite regional and genetic differences in
cancer incidence and sites, the impact of SCT on second
cancer was similar in the various studies. Collectively, TBI
was recognized as a major risk factor for nonsquamous cell
cancers, especially when administered at younger age (<30
years) [2]. Chronic GVHD was a risk factor for squamous cell
cancers, especially of the oral cavity. Advanced agewas also a
major risk factor for the occurrence of second malignancies.
The pathogenesis of second malignancies after allogeneic
SCT is multifactorial. Radiation and chemotherapy exposure
can induce breaks in the DNA double strand, resulting in
gene mutations, deletions, translocations, and genomic
instability conferred by loss of DNA repair [7]. Genomic al-
terations in mucosal epithelium, as evidenced by microsat-
ellite instability, are common, including in tissues affected by
graft-versus-host disease (GVHD), and may contribute to
second malignancies [8]. Oncogenic viruses in the context of
prolonged immune suppression may also take part in the
pathogenesis.
Reduced-intensity conditioning (RIC) has been widely
introduced over the last 15 years to allow SCT in older or
medically inﬁrm patients who are not eligible for standard
MAC. RIC has been able to markedly expand the eligible
population and the indications for SCT by reducing the
incidence of early transplantation-related complications.
One can intuitively expect that RIC will also reduce the
incidence of second malignancies [6]. However, older pa-
tients, who have often had more prior chemotherapy,
including a prior autologous SCT, are included in RIC studies.
High-dose TBI is not used; however, low-dose TBI or
chemotherapy may be even more carcinogenic as they may
leave damaged cells viable. Fludarabine, which is a major
component of RIC, has been associated with second
